Trial · NCT05805891
Bortezomib for the Treatment of Refractory Rheumatoid Arthritis
NCT05805891, Not applicable, Unknown, Chinese SLE Treatment And Research Group
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bortezomib for the Treatment of Refractory Rheumatoid Arthritis. Trials, record NCT05805891. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05805891
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bortezomib for the Treatment of Refractory Rheumatoid Arthritis
- NCT number
- NCT05805891
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Chinese SLE Treatment And Research Group
- Conditions
- Rheumatoid Arthritis
- Interventions
- bortezomib
- First posted
- 2023-04-10
- Last updated
- 2023-08-30
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | DAS28 remission or LDA at week 24 | 24 weeks | Proportion of patients who achieve remission or low disease activity (LDA) at week 24 according to DAS 28. |
| Secondary | DAS28 improvement at week 12 | 12 weeks | Proportion of patients who achieve remission or low disease activity at week 12 according to DAS 28. Proportion of patients who achieve at least a 50% reduction of DAS28 at week 12. |
| Secondary | SDAI improvement at week 12 and remission or LDA at week 24 | 24 weeks | Proportions of patients who achieve remission or low disease activity at week 12 and week 24 according to SDAI. Proportion of patients who achieve at least a 50% reduction of SDAI at week 12. |
| Secondary | CDAI improvement at week 12 and remission or LDA at week 24 | 24 weeks | Proportions of patients who achieve remission or low disease activity at week 12 and week 24 according to CDAI. Proportion of patients who achieve at least a 50% reduction of CDAI at week 12. |
| Secondary | ACR20, ACR50 and ACR70 at week 12 and week 24 | 24 weeks | Proportions of patients who achieve ACR20, ACR50 and ACR70 at week 12 and week 24. |
| Secondary | Changes in glucocorticoid dose | 24 weeks | Changes in glucocorticoid dose at week 12 and 24 from baseline. |
| Secondary | Adverse events during the study | 28 weeks | All adverse events, severe adverse events and proportion of patients who discontinued bortezomib due to adverse events from the first dose of bortezomib to 4 weeks after the last dose. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05805891
GET https://conductscience.org/api/trials/v1/NCT05805891/registered